chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This spontaneous report received from a patient via a company representative via other manufacturer concerned a 66 year old female of unspecified race and ethnicity. The patient's height, and weight were not reported. The patient's concurrent conditions included: moderate to severe rheumatoid arthritis. The patient received covid-19 vaccine ad26.cov2.s (Dose number in series 1) (suspension for injection, intramuscular, batch number was not reported, expiry: unknown) dose was not reported, 1 total, administered on 24-MAR-2021 for covid-19 prophylaxis. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. Age at time of vaccination 65 years old. No concomitant medications were reported. It was unknown whether patient had any adverse events following vaccination with first dose of covid-19 vaccine ad26. cov2.s (Dose number in series 1). The patient additionally received second dose of covid-19 vaccine (unspecified manufacturer) (Dose number in series 2) (Form, route of administration, batch number, expiry: unknown) dose were not reported administered on an unspecified date for covid-19 prophylaxis. It was unknown whether patient had any adverse events following vaccination with second dose of covid-19 vaccine (unspecified manufacturer) (Dose number in series 2). The patient received non-company suspect drugs (Rinvoq) upadacitinib (form of admin unknown, oral, batch number was not reported, expiry: unknown) dose, frequency and therapy dates were not reported for moderate to severe rheumatoid arthritis. The patient received non-company suspect vaccine (Moderna covid-19) elasomeran (Dose number in series 3) (form of admin unknown, intramuscular, batch number was not reported, expiry: unknown) dose was not reported, administered on 20-JAN-2022 for covid-19 prophylaxis. In 2022, the patient experienced covid-19 (Dose number in series 3). The action taken with covid-19 vaccine ad26.cov2.s, covid-19 vaccine, and elasomeran was not applicable; and dose of upadacitinib was not changed. The patient was recovering from covid-19. This report was non-serious.
I contracted COVID. The symptoms started with exhaustion, runny nose, a headache, and very quickly progressed to becoming a mild fever of 100. I took the afternoon off work, gave myself a COVID, and a positive result came out within a minute. Did a really strict quarantine and stayed in my room for 5 days. The fever started going down within 3 days. I been having joint ache, fatigue, and coughing. I called my doctor office and was given PAXLOVID. I took it for the 5 day course and the symptoms eased off a lot. I still have exhaustion the joint ache and the coughing though.
Within twelve hours after patient received vaccinations for FLU and PNEUMONIA simultaneouly, she suffered naso/pharyngeal inflamation and loss of speech and general malaise and weakness. She received medical care from her primary care physician who prescribed prednisone therapy.
After pt. was given shingles vaccine on 2-26-13 she developed numbness and tingling in her face (right side). Later she developed dizziness and intermittent numbness of feet and hands. Continued to have persistent/chronic paresthesias of Rt. face.
atrial fibrillation; This is a spontaneous report from a contactable consumer (patient) based on the information received by Pfizer. A 68-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection; lot number and expiry date: not known), via an unspecified route of administration on an unspecified date at a single dose for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient experienced atrial fibrillation a few days after administration on an unspecified date. The outcome of the event was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Felt faint.  Did not faint; however, assisted to floor to prevent falling/passing out.  Resolved in 30 seconds  Laid down and given water. Symptoms resolved.  Vitals WNL.  History of vasovagal reactions.  Monitored for 15 minutes and released to home.
Fever; Ache; This is a spontaneous report from a contactable consumer (patient's friend). A patient of unspecified age and gender received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: Solution for injection, lot number was not reported), via an unspecified route of administration on an unspecified date in 2021 as DOSE 1, SINGLE for covid-19 immunisation. No reactions, with the second time. The patient's medical history and concomitant medications were not reported. On an unspecified date in 2021, the patient experienced fever, ache. The outcomes of events were unknown.  The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.  This follow-up is being submitted to notify that the lot/batch number is not available despite the follow-up attempts made. Follow-up attempts have been completed and no further information is expected.
Nausea; Moderate to Severe myalgia and arthralgia; Moderate to Severe myalgia and arthralgia; Low grade fever; This is a spontaneous report from a contactable other Health Care Professional reported (Patient). A 47-year-old non- pregnant female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot Number: EL9264), via intramuscular route of administration, administered in Arm Left on 23Feb2021 at hospital (at the age of 47-year-old) as second single dose for COVID-19 immunisation. The patient medical history was not reported. No known drug allergy was reported. Concomitant medications received in two weeks of vaccination included escitalopram 5mg once a day taken for an unspecified indication, start and stop date were not reported. Patient previously received dose 1 of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot Number: EL9261), via intramuscular route of administration, administered in Arm Left on 03Feb2021 at 10:15 (at age of 47 Year of age), as a single dose for COVID-19 immunisation. The patient did not receive other vaccine in four weeks of vaccination. Patient was not diagnosed with COVID, prior vaccination. On 02Mar2021, the patient experienced moderate to severe myalgia and arthralgia, low grade fever, nausea. It was reported that adverse events resulted in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of events included muscle relaxers. On 03Mar2021, the patient underwent Covid test (Covid tested post vaccination) which included, Covid test type post vaccination: nasal swab/ COVID 19 PCR (Polymerase chain reaction) with result: negative. The outcome of the events was not recovered.  No follow-up attempts are possible. No further information is expected.
Pt got lightheaded and almost passed out after administration of her GARDASIL #2 injection.
Pt. came into store on 11/6/15 to report extensive redness, swelling, itching, and pain in the arm. She had received the vaccination on 11-4-15. She was referred to urgent care and received Rx for clindamycin.
Information has been received from a registered nurse concerning a 26 year old female with penicillin allergy who on 11-FEB-2008 was vaccinated intramuscularly with a first dose of GARDASIL (lot # reported as "1448J").  Subsequently the patient experienced an outbreak of large pimples on her face.  On an unspecified date the patient recovered from the outbreak of large pimples on her face.  Concomitant therapy included APRI.  On 11-APR-2008 the patient was vaccinated intramuscularly with a second dose of GARDASIL (lot # reported as "1757J").  On 11-APR-2008 the patient experienced diarrhea, abdominal pain, fever, headache and outbreak of large pimples on her face.  Subsequently, on 13-APR-2008, the patient recovered from diarrhea, abdominal pain, fever, headache, and outbreak of large pimples on her face.  The patient sought unspecified medical attention by calling the physician.  Additional information has been requested.
about 2 weeks after Chest Pains and going down right arm and couldn't catch breath one night and woke up next morning and felt like I had fever but no fever and body aches like the flu. went to er and they ran a bunch of test and all test were good. Said my liver and spleen was enlarged but nothing to worry about, called primary doctor and they called me in zpak took for 2 days and severe diarrhea and started breaking out in welps on 3rd day and went to er and they told me to stop zpak. Ive always been able to take this medication til now after the shot. felt alittle better after stopping zpak and then had another break out in welps 3 weeks after shot
Burning sensation on skin when touching surfaces followed by immediate drenching sweat. Any body part not touching a surface felt cool and clamy. Headache. Nausea. Malaise. Lethargy. Intense muscular fatigue. Hyperactive mind.  Insomnia. Secondary panic attack. BP elevated from typical 120 to 130 systolic up to 160 systolic for two days. Sensation of fire ants crawling along my neck. Any surface contact generated heat. Body temp never higher than 99.2 according to home thermometer. Thought i was going to die.
03/31/2021 - Swelling, rash and hardness of the right buttock and groin 04/04/2021 - Angio Edema of the face, cheek and lip.  All after the second vaccination
Information has been received from a RN concerning an elementary school aged child who ON 13-APR-1995 was vaccinated with a dose of varicella virus vaccine live. On 03-MAR-2006, the pt developed breakthrough chickenpox. Unspecified medical attention was sought. There was no product quality complaint involved. No further information was available. Additional information has been requested.
child checked after 15 minute observation and right upper leg/thigh area was red- no rash noted. no respiratory distress.   APN in room to check child and Benadryl ordered and administered. child discharged home with instructions- verbal by APN
Patient stated he never received a COVID vaccine. Pfizer was administered. Upon billing the patient's insurance, it was noted he had already received the Janssen vaccine.
Shortness of breath. Pale skin. Bruising. Petechia. Headache. Light headedness.  ventually, diagnosis of aplastic anemia. Began insidiously, became progressively worse until diagnosis due to almost passing out during exercise in late February of 2013. Hospitalized March 6, 2013.
First off the injection was not given in my deltoid muscle it was given in my bicep. Within 15 minutes of getting the vaccine I had gotten a white raised hive around the injection site that became very itchy and I began to get a red rash around the hive that was irregular. It quickly became bigger and became raised over the next few hours. It was extremely hot to the touch and painful, unlike any flu vaccine I've ever received. The next two days it continuously got bigger and more red wrapping around my arm. I went to urgent care on Sunday and it measured 9cm by 12cm. It was still very hot to the touch and bright red, itchy and painful. I was having shooting pain down my arm, numbness in my hand and fingers and itching in my hand and fingers. On Saturday night I had gotten a rash on the right side of my face and neck. From Friday night on I kept getting dizzy and light headed feeling like I was going to pass out. I have never had a reaction from any vaccines previously.
irritation; itching; red; rash at the injection site; This spontaneous case was reported by a consumer and describes the occurrence of SKIN IRRITATION (irritation), PRURITUS (itching), ERYTHEMA (red) and VACCINATION SITE RASH (rash at the injection site) in a 54-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 047A21A) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 19-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 27-Mar-2021, the patient experienced SKIN IRRITATION (irritation), PRURITUS (itching), ERYTHEMA (red) and VACCINATION SITE RASH (rash at the injection site). At the time of the report, SKIN IRRITATION (irritation), PRURITUS (itching), ERYTHEMA (red) and VACCINATION SITE RASH (rash at the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant information was reported.  Treatment drug include Triamcinolone cream.
Loss of vision in left eye. 3/22/2021 Optimal Sight 3/22/2021 Retinal Surgeons 3/30/2021 Direct Imaging MRI 4/19/2021 Eye Institute
dark bruise on breast; Headache; Sore arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Sore arm), CONTUSION (dark bruise on breast) and HEADACHE (Headache) in a 57-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 047A21A and 037A21B) for COVID-19 vaccination.     Concurrent medical conditions included Breast cancer (Right breast). Concomitant products included ANASTROZOLE, METFORMIN, PRAVASTATIN, PROPRANOLOL (PROPANOLOL [PROPRANOLOL]) and ASPIRIN [ACETYLSALICYLIC ACID] for an unknown indication.   On 17-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 12-Apr-2021, the patient experienced PAIN IN EXTREMITY (Sore arm) and HEADACHE (Headache). On 16-Apr-2021, the patient experienced CONTUSION (dark bruise on breast). At the time of the report, PAIN IN EXTREMITY (Sore arm), CONTUSION (dark bruise on breast) and HEADACHE (Headache) outcome was unknown.            No treatment information was provided. ? The patient received both scheduled doses of mRNA-1273 prior to the events; therefore, action taken with the mRNA-1273 in response to the events was not applicable. ? Action taken with mRNA-1273 in response to the event was not applicable.   Most recent FOLLOW-UP information incorporated above includes: On 18-May-2021: Updated patient email address
Non-St Elevated Myocardial Infarction.  X-rays, blood work, cardiac catheterization, CT angiogram, echo comprehensive (9/28/22);   cardiac MRI (11/28).
Pt noted pruritis in the area 9/10/09, redness and tenderness noted soon afterwards.  No history of other injury to the area.  Exam reveals 70mm X 80mm area of erythema and slight insuration.  No central lesion/bump
Adult received Pediatric dose; Adult received Pediatric dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of underdose in a 24-year-old female patient who received HBV (Engerix B pediatric) (batch number 25N39, expiry date 16-MAR-2024) for prophylaxis.   On 19-APR-2023, the patient received Engerix B pediatric. On 19-APR-2023, an unknown time after receiving Engerix B pediatric, the patient experienced underdose (Verbatim: Adult received Pediatric dose) and adult use of a child product (Verbatim: Adult received Pediatric dose). The outcome of the underdose and adult use of a child product were unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK receipt date: 20-Apr-2023 The pharmacist asked that how to proceed. The vaccine administration facility was the same as primary reporter. The reporter consented to follow-up. An adult patient received an pediatric dose of Engerix-B, which led to underdose and adult use of a child product.
This prospective pregnancy case was reported by a physician and described the occurrence of vaccine exposure during pregnancy in an unknown number of female subjects of unspecified age who were vaccinated with DTPA (with small D and P), manufacturer unspecified). On an unspecified dates the subjects received a dose of DTPa (with small D and P) (unknown details) and experienced vaccine exposure during an unknown trimester of pregnancy. The physician reported that he was administering DTPa vaccine to his pregnant subjects. Follow up was received from a nurse on 18 August 2014. The nurse was unable to identify the patient and GSK was unable to provide any patient demographics. The case has been closed as lost to follow up.
Had extreme irritability afte vaxs, 11/16/99. Mother states he was up almost all night w/crying. She did contact DR on call, who suggested acetaminophen. He was fine the next day.
Narrative: Patient reported diarrhea following 1st dose of Pfizer covid vaccine. Resolved without intervention.
12/24/2020  chills body aches headache, fever off and on.  onest pain, shortness of breath
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a contactable reporter(s) (Other HCP). The reporter is the patient.  A 44-year-old male patient received BNT162b2 (BNT162B2), on 18Dec2020 at 05:30 as dose 1, single (Lot number: Ej1685), in left arm, on 08Jan2021 at 06:00 as dose 2, single (Lot number: El1283), in left arm and on 27Sep2021 at 17:00 as dose 3 (booster), single (Lot number: Fe3592) at the age of 42 years, in left arm for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: positive, notes: Rebound Covid positive after taking paxlovid; Unknown results, notes: Indication: Covid-19 treatment. Therapeutic measures were taken as a result of drug ineffective, covid-19.  Additional information: The patient did not receive any other medication in 2weeks. Other medical history: None.  No follow-up attempts are possible. No further information is expected. OR  No follow-up attempts are needed. No further information is expected.
This spontaneous case reported by a consumer, describes the occurrence of pyrexia (temperature over 100 degrees for 24 hours) in a 66-year-old male patient who received mRNA-1273 (Moderna COVID-19 vaccine, batch/lot# 010A21A) for COVID-19  immunization. No medical history reported. On Feb 27, 2021, patient received the first dose of mRNA-1273 (Moderna COVID-19 vaccine), intramuscular; 1 dosage form. In June 2021, received second dose of mRNA-1273 (Moderna COVID-19 vaccine), unknown route; 1 dosage form. On an unknown date, patient experienced pyrexia (temperature over 100 degrees for 24 hours). At the time of the report, pyrexia (temperature over 100 degrees for 24 hours) outcome: unknown. Diagnostic results: On an unknown date, body temperature: 100 (high) temperature over 100 degrees for 24 hours. On an unknown date, heart rate: abnormal. Had fast heart rate. No concomitant medication or treatment information reported. The action taken with mRNA-1273 (Moderna COVID-19 vaccine) in response to the events: not applicable. This case linked to MOD-2021-251494 (patient link).
My Sister was found dead on 4/27/2021. She had been dead aprx. 0ne week. She received her 1st Moderna shot on March 25th.
Upper left arm became red and swollen on day 2. Day 3 re splotches on entire upper arm and pain increased. Unable to lift arm above shoulder. Day 4 resolved.
Patient admitted to hospital with positive COVID-19 breakthrough case. Only received 1st dose per vaccine database.
Patient complaining of Weakness, evaluation demonstrated worsening of the pneumonia from 1 month ago. In addition, the patient had acute kidney injury, hypomagnesemia, hypokalemia, and hypotension. Treated and follow up with PCP. ED visit and hospital admission within 6 weeks of receiving the COVID vaccine.
Arm had a reaction with big swelling; it's still red and itchy; it's still red and itchy; Bumps in arm; This spontaneous case was reported by a consumer and describes the occurrence of PERIPHERAL SWELLING (Arm had a reaction with big swelling), ERYTHEMA (it's still red and itchy), PRURITUS (it's still red and itchy) and RASH PAPULAR (Bumps in arm) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 0121A0A/ 012NE0A) for COVID-19 vaccination.     No Medical History information was reported.    On 03-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-Feb-2021, the patient experienced PERIPHERAL SWELLING (Arm had a reaction with big swelling), ERYTHEMA (it's still red and itchy), PRURITUS (it's still red and itchy) and RASH PAPULAR (Bumps in arm). The patient was treated with HYDROCORTISONE at an unspecified dose and frequency. At the time of the report, PERIPHERAL SWELLING (Arm had a reaction with big swelling), ERYTHEMA (it's still red and itchy) and PRURITUS (it's still red and itchy) was resolving and RASH PAPULAR (Bumps in arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications was not provided by the reporter.
burning; itching; rash around her neck; swelling of the lymph nodes in the same site of the injection; rash reaction in her arm/covid arm; This spontaneous case was reported by a patient and describes the occurrence of BURNING SENSATION (burning), PRURITUS (itching), RASH (rash around her neck), VACCINATION SITE LYMPHADENOPATHY (swelling of the lymph nodes in the same site of the injection) and VACCINATION SITE RASH (rash reaction in her arm/covid arm) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 24-May-2022, the patient received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced BURNING SENSATION (burning), PRURITUS (itching), RASH (rash around her neck), VACCINATION SITE LYMPHADENOPATHY (swelling of the lymph nodes in the same site of the injection) and VACCINATION SITE RASH (rash reaction in her arm/covid arm). At the time of the report, BURNING SENSATION (burning), PRURITUS (itching), RASH (rash around her neck), VACCINATION SITE LYMPHADENOPATHY (swelling of the lymph nodes in the same site of the injection) and VACCINATION SITE RASH (rash reaction in her arm/covid arm) outcome was unknown.            No concomitant medications was reported. Patient asked if itching was an allergy. Patient did not provide any other information on the event. No treatment medications was reported.   This case was linked to MOD-2022-650771 (Patient Link).   Reporter did not allow further contact